These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18570964)

  • 1. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
    Yang L; Sanchez A; Ward JM; Murphy BR; Collins PL; Bukreyev A
    Virology; 2008 Aug; 377(2):255-64. PubMed ID: 18570964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.
    Bukreyev AA; Dinapoli JM; Yang L; Murphy BR; Collins PL
    Virology; 2010 Apr; 399(2):290-8. PubMed ID: 20129638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
    Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
    J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
    Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2017 May; 91(10):. PubMed ID: 28250127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
    DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
    Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful topical respiratory tract immunization of primates against Ebola virus.
    Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
    J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
    Bukreyev A; Marzi A; Feldmann F; Zhang L; Yang L; Ward JM; Dorward DW; Pickles RJ; Murphy BR; Feldmann H; Collins PL
    Virology; 2009 Jan; 383(2):348-61. PubMed ID: 19010509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
    Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
    J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
    Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
    Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
    Locher S; Schweneker M; Hausmann J; Zimmer G
    J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs.
    Yoshida A; Kim SH; Manoharan VK; Varghese BP; Paldurai A; Samal SK
    Sci Rep; 2019 Apr; 9(1):5520. PubMed ID: 30940854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
    J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
    Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
    J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 19. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
    Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.